| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | BUY | BUY | BUY | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.42▼ | 1.42▲ | 1.41▲ | 1.37▲ | 1.42▼ |
| MA10 | 1.43▼ | 1.41▲ | 1.43▼ | 1.37▲ | 1.46▼ |
| MA20 | 1.42▼ | 1.43▼ | 1.40▲ | 1.40▲ | 2.03▼ |
| MA50 | 1.43▼ | 1.35▲ | 1.36▲ | 1.58▼ | 2.12▼ |
| MA100 | 1.37▲ | 1.35▲ | 1.36▲ | 2.02▼ | 4.14▼ |
| MA200 | 1.36▲ | 1.39▲ | 1.46▼ | 2.01▼ | 8.99▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.001▼ | -0.005▼ | -0.003▼ | 0.024▲ | -0.066▼ |
| RSI | 47.478▼ | 54.520▲ | 54.710▲ | 46.016▼ | 40.566▼ |
| STOCH | 15.278▼ | 28.571 | 19.048▼ | 49.704 | 20.909 |
| WILL %R | -100.000▼ | -71.429 | -71.429 | -42.857 | -86.667▼ |
| CCI | -111.111▼ | -18.462 | -22.525 | 112.530▲ | -54.653 |
|
Tuesday, November 25, 2025 03:03 AM
Philipson will serve as a strategic advisor to Soligenix, contributing extensive expertise in U.S. economic policy, healthcare regulation and corporate strategy. The significance of this appointment ...
|
|
Thursday, November 20, 2025 10:06 AM
SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Enrollment in FLASH2 Trial Reaches 50; Interim Analysis in 2Q26 On November 19, 2025, Soligenix, Inc. (NASDAQ:SNGX) announced that enrollment in ...
|
|
Wednesday, November 19, 2025 01:28 PM
Following the first Phase 3 study of HyBryte(TM) for the treatment of CTCL, the FDA and the EMA indicated that they would require a second successful Phase 3 trial to support mark ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 25/11/25 | 1.42 | 1.47 | 1.36 | 1.41 | 222,600 |
| 24/11/25 | 1.35 | 1.53 | 1.35 | 1.43 | 445,900 |
| 21/11/25 | 1.26 | 1.43 | 1.26 | 1.41 | 233,400 |
| 20/11/25 | 1.34 | 1.36 | 1.26 | 1.27 | 294,100 |
| 19/11/25 | 1.40 | 1.47 | 1.29 | 1.32 | 555,400 |
| 18/11/25 | 1.30 | 1.39 | 1.30 | 1.37 | 180,489 |
| 17/11/25 | 1.37 | 1.40 | 1.34 | 1.35 | 114,100 |
| 14/11/25 | 1.32 | 1.41 | 1.30 | 1.37 | 89,800 |
| 13/11/25 | 1.39 | 1.40 | 1.25 | 1.38 | 405,500 |
| 12/11/25 | 1.41 | 1.44 | 1.35 | 1.36 | 118,400 |
|
|
||||
|
|
||||
|
|